Twist Bioscience Corp
Company Profile
Business description
Twist Bioscience Corp provides customizable solutions across the biological continuum, helping customers read, write and innovate in biology. The core of its business is a proprietary platform that allows it to manufacture synthetic DNA by writing DNA on a silicon chip. The company operates as one reportable and operating segment, through which it develops, manufactures and sells DNA Synthesis and Protein Solutions and NGS Applications products and services. It has presence in Americas, EMEA, and APAC. Majority of revenue comes from Americas. Its products are Genes, Oligo Pools, NGS, Variant Libraries, Synthetic Controls, Antibody Discovery, and VDR Solutions.
Contact
681 Gateway Boulevard
South San FranciscoCA94080
USAT: +1 800 719-0671
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2027
Employees
1,080
Stocks News & Analysis
stocks
This defensive ASX listed REIT offers a 5% yield
stocks
Chart of the Week: Anthropic’s IPO range sits below our fair value
stocks
Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,932.40 | 64.90 | -0.72% |
| CAC 40 | 8,146.83 | 69.95 | -0.85% |
| DAX 40 | 25,736.24 | 309.13 | -1.19% |
| Dow JONES (US) | 50,215.35 | 544.07 | -1.07% |
| FTSE 100 | 10,551.17 | 138.70 | -1.30% |
| HKSE | 23,294.75 | 213.42 | -0.91% |
| NASDAQ | 24,436.16 | 107.78 | 0.44% |
| Nikkei 225 | 59,024.28 | 163.85 | 0.28% |
| NZX 50 Index | 14,264.29 | 42.67 | -0.30% |
| S&P 500 | 7,326.76 | 13.77 | -0.19% |
| S&P/ASX 200 | 8,821.80 | 61.40 | -0.69% |
| SSE Composite Index | 3,587.83 | 3.25 | 0.09% |